- Home
- IMAX vs IRON Comparison
IMAX vs IRON Comparison
Compare IMAX & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAX
- IRON
- Stock Information
- Founded
- IMAX 1967
- IRON 2017
- Country
- IMAX Canada
- IRON United States
- Employees
- IMAX N/A
- IRON N/A
- Industry
- IMAX
- IRON Biotechnology: Pharmaceutical Preparations
- Sector
- IMAX
- IRON Health Care
- Exchange
- IMAX Nasdaq
- IRON Nasdaq
- Market Cap
- IMAX 1.8B
- IRON 2.1B
- IPO Year
- IMAX 1994
- IRON N/A
- Fundamental
- Price
- IMAX $32.58
- IRON $84.66
- Analyst Decision
- IMAX Strong Buy
- IRON Strong Buy
- Analyst Count
- IMAX 9
- IRON 13
- Target Price
- IMAX $35.78
- IRON $106.92
- AVG Volume (30 Days)
- IMAX 1.1M
- IRON 602.0K
- Earning Date
- IMAX 10-23-2025
- IRON 11-07-2025
- Dividend Yield
- IMAX N/A
- IRON N/A
- EPS Growth
- IMAX 62.41
- IRON N/A
- EPS
- IMAX 0.71
- IRON N/A
- Revenue
- IMAX $377,677,000.00
- IRON N/A
- Revenue This Year
- IMAX $17.86
- IRON N/A
- Revenue Next Year
- IMAX $6.18
- IRON N/A
- P/E Ratio
- IMAX $45.86
- IRON N/A
- Revenue Growth
- IMAX 9.30
- IRON N/A
- 52 Week Low
- IMAX $20.48
- IRON $30.82
- 52 Week High
- IMAX $34.14
- IRON $95.95
- Technical
- Relative Strength Index (RSI)
- IMAX 56.43
- IRON 61.08
- Support Level
- IMAX $31.44
- IRON $83.95
- Resistance Level
- IMAX $33.37
- IRON $89.79
- Average True Range (ATR)
- IMAX 1.08
- IRON 4.05
- MACD
- IMAX -0.02
- IRON -0.33
- Stochastic Oscillator
- IMAX 55.51
- IRON 52.24
About IMAX Imax Corporation
Imax Corp is a technology platform for entertainment and events. Through its proprietary software, auditorium architecture, patented intellectual property, and specialized equipment, IMAX offers end-to-end solution to create superior, immersive content experiences for which the IMAX brand is globally renowned. The Company has two reportable segments being Content Solutions and Technology Products and Services. The Company leverages its proprietary technology and engineering in all aspects of its business, which principally consists of the IMAX film remastering and the sale or lease of premium IMAX theater systems.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.